NZ210501A
(en)
|
1983-12-13 |
1991-08-27 |
Kirin Amgen Inc |
Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
|
US4703008A
(en)
|
1983-12-13 |
1987-10-27 |
Kiren-Amgen, Inc. |
DNA sequences encoding erythropoietin
|
KR850004274A
(ko)
|
1983-12-13 |
1985-07-11 |
원본미기재 |
에리트로포이에틴의 제조방법
|
JP2983629B2
(ja)
|
1989-10-13 |
1999-11-29 |
キリン―アムジエン・インコーポレイテツド |
エリスロポエチンイソフォーム
|
US7217689B1
(en)
|
1989-10-13 |
2007-05-15 |
Amgen Inc. |
Glycosylation analogs of erythropoietin
|
US5856298A
(en)
|
1989-10-13 |
1999-01-05 |
Amgen Inc. |
Erythropoietin isoforms
|
IL192290A0
(en)
|
1993-08-17 |
2008-12-29 |
Kirin Amgen Inc |
Erythropoietin analogs
|
US6562596B1
(en)
|
1993-10-06 |
2003-05-13 |
Amgen Inc. |
Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
|
US5773569A
(en)
|
1993-11-19 |
1998-06-30 |
Affymax Technologies N.V. |
Compounds and peptides that bind to the erythropoietin receptor
|
US5830851A
(en)
|
1993-11-19 |
1998-11-03 |
Affymax Technologies N.V. |
Methods of administering peptides that bind to the erythropoietin receptor
|
US5885574A
(en)
|
1994-07-26 |
1999-03-23 |
Amgen Inc. |
Antibodies which activate an erythropoietin receptor
|
ATE306930T1
(de)
|
1994-08-12 |
2005-11-15 |
Immunomedics Inc |
Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
|
US5686292A
(en)
|
1995-06-02 |
1997-11-11 |
Genentech, Inc. |
Hepatocyte growth factor receptor antagonist antibodies and uses thereof
|
US5767078A
(en)
|
1995-06-07 |
1998-06-16 |
Johnson; Dana L. |
Agonist peptide dimers
|
NZ502375A
(en)
|
1997-07-14 |
2001-11-30 |
Bolder Biotechnology Inc |
The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family
|
US6753165B1
(en)
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
PT986644E
(pt)
|
1997-07-23 |
2007-01-31 |
Roche Diagnostics Gmbh |
Preparação de eritropoietina por activação genética endógena com promotores virais
|
US6030086A
(en)
|
1998-03-02 |
2000-02-29 |
Becton, Dickinson And Company |
Flash tube reflector with arc guide
|
US6310078B1
(en)
|
1998-04-20 |
2001-10-30 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituted amino acids as erythropoietin mimetics
|
US20050181482A1
(en)
|
2004-02-12 |
2005-08-18 |
Meade Harry M. |
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
|
ES2273497T3
(es)
|
1998-06-15 |
2007-05-01 |
Gtc Biotherapeutics, Inc. |
Proteina de fusion de la albumina serica humana de eritropoyetina analoga.
|
AR020848A1
(es)
|
1998-10-23 |
2002-05-29 |
Amgen Inc |
Metodos y composiciones para la prevencion y el tratamiento de anemia
|
CN1810832B
(zh)
|
1998-10-23 |
2012-12-12 |
麒麟-安姆根有限公司 |
与MPl受体结合并具有血小板生成活性的模拟二聚体血小板生成素肽
|
US6395511B1
(en)
|
1998-11-27 |
2002-05-28 |
Darwin Discovery, Ltd. |
Nucleic acids encoding a novel family of TGF-β binding proteins from humans
|
EP1006184A1
(en)
|
1998-12-03 |
2000-06-07 |
F. Hoffmann-La Roche Ag |
IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
|
WO2000061637A1
(en)
|
1999-04-14 |
2000-10-19 |
Smithkline Beecham Corporation |
Erythropoietin receptor antibodies
|
US7297680B2
(en)
|
1999-04-15 |
2007-11-20 |
Crucell Holland B.V. |
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
|
CZ299516B6
(cs)
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
US6102896A
(en)
*
|
1999-09-08 |
2000-08-15 |
Cambridge Biostability Limited |
Disposable injector device
|
JP2003512840A
(ja)
|
1999-10-22 |
2003-04-08 |
ミレニアム・ファーマシューティカルズ・インコーポレイテッド |
ラット脳に由来する核酸分子およびプログラム細胞死モデル
|
US20050202538A1
(en)
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
EP1228214A2
(en)
|
1999-11-12 |
2002-08-07 |
MERCK PATENT GmbH |
Erythropoietin forms with improved properties
|
DE60107203T3
(de)
|
2000-01-21 |
2009-07-23 |
Biovex Ltd. |
Herpes-virusstämme für die gentherapie
|
AUPQ599700A0
(en)
|
2000-03-03 |
2000-03-23 |
Super Internet Site System Pty Ltd |
On-line geographical directory
|
US6586398B1
(en)
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
CA2406807C
(en)
|
2000-04-21 |
2010-04-06 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
US6756480B2
(en)
|
2000-04-27 |
2004-06-29 |
Amgen Inc. |
Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
|
US7078376B1
(en)
|
2000-08-11 |
2006-07-18 |
Baxter Healthcare S.A. |
Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
|
RU2003109746A
(ru)
|
2000-09-08 |
2005-01-27 |
Грифон Терапьютикс, Инк. (Us) |
Синтетические белки, стимулирующие эритропоэз
|
US7271689B1
(en)
|
2000-11-22 |
2007-09-18 |
Fonar Corporation |
Magnet structure
|
ATE505204T1
(de)
|
2000-12-20 |
2011-04-15 |
Hoffmann La Roche |
Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
|
AR032028A1
(es)
|
2001-01-05 |
2003-10-22 |
Pfizer |
Anticuerpos contra el receptor del factor de crecimiento similar a insulina
|
JP2005503127A
(ja)
|
2001-04-04 |
2005-02-03 |
ジェンオディセ |
エリスロポエチン遺伝子の新規ポリヌクレオチド及びポリペプチド
|
ES2527471T3
(es)
|
2001-05-11 |
2015-01-26 |
Amgen Inc. |
Péptidos y moléculas relacionadas que se unen a TALL-1
|
PL222211B1
(pl)
|
2001-06-26 |
2016-07-29 |
Amgen Fremont Inc |
Przeciwciało przeciwko OPGL, kompozycja je zawierająca, jego zastosowanie i sposób jego wytwarzania, sposób wykrywania poziomu OPGL, kompozycja obejmująca polinukleotydy i komórka gosodarza
|
US6900292B2
(en)
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
JP4359503B2
(ja)
|
2001-08-23 |
2009-11-04 |
ゲンマブ エー/エス |
インターロイキン15(il−15)に特異的なヒト抗体
|
US7247304B2
(en)
|
2001-08-23 |
2007-07-24 |
Genmab A/S |
Methods of treating using anti-IL-15 antibodies
|
US6930086B2
(en)
|
2001-09-25 |
2005-08-16 |
Hoffmann-La Roche Inc. |
Diglycosylated erythropoietin
|
US7214660B2
(en)
|
2001-10-10 |
2007-05-08 |
Neose Technologies, Inc. |
Erythropoietin: remodeling and glycoconjugation of erythropoietin
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
GB0125506D0
(en)
*
|
2001-10-24 |
2001-12-12 |
Weston Medical Ltd |
Needle free injection method and apparatus
|
TWI222370B
(en)
*
|
2001-12-14 |
2004-10-21 |
Roche Diagnostics Gmbh |
Needleless hypodermic injection device
|
WO2003055526A2
(en)
|
2001-12-21 |
2003-07-10 |
Maxygen Aps |
Erythropoietin conjugates
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
JP4606739B2
(ja)
|
2002-01-18 |
2011-01-05 |
ピエール、ファーブル、メディカマン |
新規抗igf−ir抗体およびその使用
|
WO2003064664A1
(en)
|
2002-01-31 |
2003-08-07 |
Oxford Biomedica (Uk) Limited |
Physiologically regulated erythropoietin- exprressing vector for the treatment of anaemia
|
GB0202252D0
(en)
|
2002-01-31 |
2002-03-20 |
Oxford Biomedica Ltd |
Anemia
|
ATE363541T1
(de)
|
2002-03-26 |
2007-06-15 |
Lek Tovarna Farmacevtskih |
Verfahren für die herstellung eines gewünschten profils von erythropoietin glyko-isoformen
|
EP1572079A4
(en)
|
2002-03-29 |
2006-09-06 |
Centocor Inc |
MAMMAL-CDR MIMETIC BODIES, COMPOSITIONS, PROCESSES AND APPLICATION PURPOSES
|
BRPI0308946B1
(pt)
|
2002-03-29 |
2016-08-30 |
Kumiai Chemical Industry Co |
ácido nucleico, proteína, vetor recombinante, bactéria, processos para cultivar planta que apresenta o referido ácido nucleico, para cultivar planta que apresenta a referida proteína, para seleção de célula transformante que apresenta o referido ácido nucleico e para selecionar célula transformante que apresenta a referida proteína
|
WO2003094858A2
(en)
|
2002-05-13 |
2003-11-20 |
Modigenetech Ltd. |
Ctp-extended erythropoietin
|
WO2003100008A2
(en)
|
2002-05-24 |
2003-12-04 |
Schering Corporation |
Neutralizing human anti-igfr antibody
|
US8034904B2
(en)
|
2002-06-14 |
2011-10-11 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
US7538195B2
(en)
|
2002-06-14 |
2009-05-26 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
KR20050033563A
(ko)
|
2002-06-28 |
2005-04-12 |
센토코 인코포레이티드 |
포유동물 epo 모방 ch1 결실된 모방체, 조성물, 방법및 용도
|
EP1545608A4
(en)
|
2002-06-28 |
2006-09-13 |
Centocor Inc |
CH1-DELETED MAMMED MUICETIC BODIES, COMPOSITIONS, METHODS AND APPLICATIONS
|
WO2004009627A1
(en)
|
2002-07-19 |
2004-01-29 |
Cangene Corporation |
Pegylated erythropoietic compounds
|
SE0202350D0
(sv)
*
|
2002-07-31 |
2002-07-31 |
Pharmacia Ab |
Device and method for liquid jet generation
|
TW200413406A
(en)
|
2002-08-26 |
2004-08-01 |
Kirin Brewery |
Peptides and drugs containing the same
|
NZ593428A
(en)
|
2002-09-06 |
2013-01-25 |
Amgen Inc |
Therapeutic human anti-il-1r1 monoclonal antibody
|
BR0314107A
(pt)
|
2002-09-11 |
2005-07-19 |
Fresenius Kabi De Gmbh |
Método de produção de derivados de hidroxialquil amido
|
US6919426B2
(en)
|
2002-09-19 |
2005-07-19 |
Amgen Inc. |
Peptides and related molecules that modulate nerve growth factor activity
|
US7396913B2
(en)
|
2002-10-14 |
2008-07-08 |
Abbott Laboratories |
Erythropoietin receptor binding antibodies
|
US20040071694A1
(en)
|
2002-10-14 |
2004-04-15 |
Devries Peter J. |
Erythropoietin receptor binding antibodies
|
TWI320716B
(en)
|
2002-10-14 |
2010-02-21 |
Abbott Lab |
Erythropoietin receptor binding antibodies
|
WO2004034988A2
(en)
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
|
US20040091961A1
(en)
|
2002-11-08 |
2004-05-13 |
Evans Glen A. |
Enhanced variants of erythropoietin and methods of use
|
KR20130036378A
(ko)
|
2002-12-20 |
2013-04-11 |
암겐 인코포레이티드 |
미오스타틴을 저해하는 결합제
|
EP1603948A1
(en)
|
2003-03-14 |
2005-12-14 |
Pharmacia Corporation |
Antibodies to igf-i receptor for the treatment of cancers
|
JP4473257B2
(ja)
|
2003-04-02 |
2010-06-02 |
エフ.ホフマン−ラ ロシュ アーゲー |
インスリン様成長因子i受容体に対する抗体及びその使用
|
US7220410B2
(en)
|
2003-04-18 |
2007-05-22 |
Galaxy Biotech, Llc |
Monoclonal antibodies to hepatocyte growth factor
|
WO2005016970A2
(en)
|
2003-05-01 |
2005-02-24 |
Imclone Systems Incorporated |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
MXPA05012313A
(es)
|
2003-05-12 |
2006-04-18 |
Affymax Inc |
Peptidos que se unen al receptor de eritropoyetina.
|
BRPI0411160A
(pt)
|
2003-05-12 |
2006-07-11 |
Affymax Inc |
novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
|
ATE428727T1
(de)
|
2003-05-12 |
2009-05-15 |
Affymax Inc |
Neue, an den erythropoietinrezeptor bindende peptide
|
US7074755B2
(en)
|
2003-05-17 |
2006-07-11 |
Centocor, Inc. |
Erythropoietin conjugate compounds with extended half-lives
|
KR20060032140A
(ko)
|
2003-05-30 |
2006-04-14 |
센토코 인코포레이티드 |
트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
|
US20050037390A1
(en)
|
2003-06-04 |
2005-02-17 |
Irm Llc, A Delaware Limited Liability Company |
Methods and compositions for modulating erythropoietin expression
|
AR046071A1
(es)
|
2003-07-10 |
2005-11-23 |
Hoffmann La Roche |
Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
|
NZ544751A
(en)
|
2003-07-15 |
2009-05-31 |
Amgen Inc |
Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
|
JP5105874B2
(ja)
|
2003-07-18 |
2012-12-26 |
アムジエン・インコーポレーテツド |
肝細胞増殖因子に対する特異的結合因子
|
US20050019914A1
(en)
|
2003-07-24 |
2005-01-27 |
Aventis Pharma Deutschland Gmbh |
Perfusion process for producing erythropoietin
|
GB0317511D0
(en)
|
2003-07-25 |
2003-08-27 |
Biovex Ltd |
Viral vectors
|
WO2005021579A2
(en)
|
2003-08-28 |
2005-03-10 |
Biorexis Pharmaceutical Corporation |
Epo mimetic peptides and fusion proteins
|
BRPI0409650A
(pt)
|
2003-09-09 |
2006-04-25 |
Warren Pharmaceuticals Inc |
métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica
|
UA89481C2
(uk)
|
2003-09-30 |
2010-02-10 |
Центокор, Инк. |
Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
|
JP4767857B2
(ja)
|
2003-09-30 |
2011-09-07 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
ベンゾイミダゾール化合物
|
AU2004290017B2
(en)
|
2003-11-07 |
2012-05-03 |
Immunex Corporation |
Antibodies that bind interleukin-4 receptor
|
TW200526684A
(en)
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
US8633157B2
(en)
|
2003-11-24 |
2014-01-21 |
Novo Nordisk A/S |
Glycopegylated erythropoietin
|
EP1694347B1
(en)
|
2003-11-24 |
2013-11-20 |
BioGeneriX AG |
Glycopegylated erythropoietin
|
WO2005058967A2
(en)
|
2003-12-16 |
2005-06-30 |
Pierre Fabre Medicament |
Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
|
EP1548031A1
(en)
|
2003-12-22 |
2005-06-29 |
Dubai Genetics FZ-LLC |
Nature-identical erythropoietin
|
JP2008500275A
(ja)
|
2003-12-31 |
2008-01-10 |
セントカー・インコーポレーテツド |
N末端の遊離チオールを有する新規な組み換えタンパク質
|
PT1699821E
(pt)
|
2003-12-31 |
2012-08-23 |
Merck Patent Gmbh |
Proteína de fusão fc-eritropoietina com farmacocinética melhorada
|
US7423139B2
(en)
|
2004-01-20 |
2008-09-09 |
Insight Biopharmaceuticals Ltd. |
High level expression of recombinant human erythropoietin having a modified 5′-UTR
|
US20050187158A1
(en)
|
2004-01-22 |
2005-08-25 |
Ranby Mats G. |
Pharmaceutical composition
|
WO2005084711A1
(fr)
|
2004-03-02 |
2005-09-15 |
Chengdu Institute Of Biological Products |
Erythropoietine recombinante pegylee a activite in vivo
|
WO2005092369A2
(en)
|
2004-03-11 |
2005-10-06 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyethyl starch and erythropoietin
|
MXPA06010887A
(es)
|
2004-03-23 |
2007-03-08 |
Amgen Inc |
Anticuerpos monoclonales especificos para ox4ol (cd 134l) humano.
|
US20050227289A1
(en)
|
2004-04-09 |
2005-10-13 |
Reilly Edward B |
Antibodies to erythropoietin receptor and uses thereof
|
CA2563874A1
(en)
|
2004-04-23 |
2005-11-03 |
Cambridge Antibody Technology Limited |
Erythropoietin protein variants
|
BRPI0513029A
(pt)
|
2004-07-07 |
2008-04-22 |
Lundbeck & Co As H |
método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
|
FR2873699B1
(fr)
|
2004-07-29 |
2009-08-21 |
Pierre Fabre Medicament Sa |
Nouveaux anticorps anti igf ir rt leurs utilisations
|
US20060073563A1
(en)
|
2004-09-02 |
2006-04-06 |
Xencor, Inc. |
Erythropoietin derivatives with altered immunogenicity
|
EP1812461A2
(en)
|
2004-11-10 |
2007-08-01 |
AplaGen GmbH |
Molecules which promote hematopoiesis
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
WO2006081171A1
(en)
|
2005-01-24 |
2006-08-03 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
CN101613409B
(zh)
|
2005-06-17 |
2014-06-04 |
英克隆有限责任公司 |
抗-PDGFRα抗体
|
WO2007000328A1
(en)
|
2005-06-27 |
2007-01-04 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
|
EP2388277A3
(en)
|
2005-07-18 |
2013-03-20 |
Amgen, Inc |
Human anti-B7RP1 neutralizing antibodies
|
FR2888850B1
(fr)
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
PE20071101A1
(es)
|
2005-08-31 |
2007-12-21 |
Amgen Inc |
Polipeptidos y anticuerpos
|
GB0603683D0
(en)
|
2006-02-23 |
2006-04-05 |
Novartis Ag |
Organic compounds
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
EP2032600A2
(en)
|
2006-05-19 |
2009-03-11 |
Glycofi, Inc. |
Erythropoietin compositions
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
EP2076302A1
(de)
*
|
2006-09-15 |
2009-07-08 |
TecPharma Licensing AG |
Injektionsgerät mit automatisch rückstellbarer dosisbegrenzungseinrichtung
|
CA2667894A1
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
EP2083860A4
(en)
|
2006-11-07 |
2010-05-26 |
Merck Sharp & Dohme |
PCSK9 ANTAGONISTS
|
EP2083859A4
(en)
|
2006-11-07 |
2010-11-24 |
Merck Sharp & Dohme |
ANTAGONISTS OF PCSK9
|
CA2667989A1
(en)
|
2006-11-07 |
2008-11-06 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
EP2628752A1
(en)
|
2006-12-14 |
2013-08-21 |
Merck Sharp & Dohme Corp. |
Engineered anti-TSLP antibody
|
AR066042A1
(es)
|
2007-04-13 |
2009-07-22 |
Novartis Ag |
Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
|
CA2691157A1
(en)
|
2007-06-20 |
2008-12-24 |
Irm Llc |
Methods and compositions for treating allergic diseases
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
EP2192938B1
(en)
*
|
2007-09-18 |
2017-10-25 |
SHL Group AB |
Automatic injection device with needle insertion
|
WO2009055783A2
(en)
|
2007-10-26 |
2009-04-30 |
Schering Corporation |
Anti-pcsk9 and methods for treating lipid and cholesterol disorders
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
EP3017837B1
(en)
*
|
2008-10-29 |
2017-02-01 |
SHL Group AB |
Injection device
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
EP2480576A4
(en)
|
2009-09-25 |
2013-04-10 |
Merck Sharp & Dohme |
ANTAGONISTS OF PCSK9
|
JP2013509194A
(ja)
|
2009-10-30 |
2013-03-14 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ax213およびax132pcsk9アンタゴニストおよびバリアント
|
EP2493505A4
(en)
|
2009-10-30 |
2013-06-12 |
Merck Sharp & Dohme |
AX1 AND AX189 PCSK9 ANTAGONISTS AND VARIANTS THEREOF
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
WO2011111007A2
(en)
|
2010-03-11 |
2011-09-15 |
Rinat Neuroscience Corporation |
ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
|
EP2399630A1
(en)
*
|
2010-06-28 |
2011-12-28 |
Sanofi-Aventis Deutschland GmbH |
Auto-injector
|
EP2399631A1
(en)
*
|
2010-06-28 |
2011-12-28 |
Sanofi-Aventis Deutschland GmbH |
Auto-injector with injection damper
|
EP2438947A1
(en)
*
|
2010-10-08 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Auto-injector
|
WO2012054438A1
(en)
|
2010-10-22 |
2012-04-26 |
Schering Corporation |
Anti-pcsk9
|
MA34818B1
(fr)
|
2010-12-22 |
2014-01-02 |
Genentech Inc |
Anticorps anti-pcsk9 et procédés d'utilisation
|
WO2012101253A1
(en)
|
2011-01-28 |
2012-08-02 |
Sanofi |
Pharmaceutical compositions comprising human antibodies to pcsk9
|
CN103562227B
(zh)
|
2011-02-11 |
2016-12-21 |
诺瓦提斯公司 |
Pcsk9拮抗剂
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
US9408972B2
(en)
*
|
2011-08-02 |
2016-08-09 |
Pharmajet, Inc. |
Needle-free injection device
|
CH705692A2
(de)
*
|
2011-11-03 |
2013-05-15 |
Tecpharma Licensing Ag |
Verabreichungsvorrichtung zum Abmischen eines Wirkstoffs mit einer Lösungsflüssigkeit.
|
JP6426107B2
(ja)
|
2012-12-20 |
2018-11-21 |
アムジエン・インコーポレーテツド |
Apj受容体アゴニストおよびその使用
|
CN105025965B
(zh)
*
|
2013-03-13 |
2019-07-05 |
赛诺菲-安万特德国有限公司 |
用于药物输送装置的包括反馈特征部的组件
|
JP2016513666A
(ja)
|
2013-03-14 |
2016-05-16 |
アムジエン・インコーポレーテツド |
組織メタロプロテイナーゼ阻害物質3型(timp−3)の変異体、組成物、及び方法
|
US20140274874A1
(en)
|
2013-03-14 |
2014-09-18 |
Amgen Inc. |
Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
|
US20160038677A1
(en)
*
|
2013-04-19 |
2016-02-11 |
Novo Nordisk A/S |
Drug Delivery Device with Compact Power Unit
|
SG11201609219QA
(en)
*
|
2014-05-07 |
2016-12-29 |
Amgen Inc |
Autoinjector with shock reducing elements
|
GB201501705D0
(en)
*
|
2015-02-02 |
2015-03-18 |
Atlas Genetics Ltd |
Instrument for performing a diagnostic test on a fluidic cartridge
|
CH711240A2
(de)
*
|
2015-06-23 |
2016-12-30 |
Tecpharma Licensing Ag |
Autoinjektionsvorrichtung.
|
GB2541915A
(en)
*
|
2015-09-03 |
2017-03-08 |
Owen Mumford Ltd |
Medicament delivery devices
|
GB2549750A
(en)
*
|
2016-04-27 |
2017-11-01 |
Owen Mumford Ltd |
Medicament delivery device
|
US11541176B2
(en)
*
|
2016-06-03 |
2023-01-03 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|